Skip to content
Back to treatments
Oncology~83% less than U.S.

Multiple Myeloma Treatment

多发性骨髓瘤治疗

Duration
6-12 months initial treatment, maintenance ongoing
Recovery
3-4 weeks after transplant, ongoing during maintenance therapy
Average savings
83%
价格对比Price comparison

China versus the U.S.

China
$50,000
Range: $20,000–$80,000
United States
$300,000
Range: $100,000–$500,000
You save
83%
~$250,000 per procedure
China clinical rate
$20,000 – $80,000
$50,000
United States
$100,000 – $500,000
$300,000
You save
~83%
$250,000 per procedure

Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.

关于About this treatment

What the procedure involves.

Multiple myeloma treatment in China utilizes modern induction regimens (VRd — bortezomib, lenalidomide, dexamethasone) followed by autologous stem cell transplant for eligible patients, with maintenance therapy. Chinese hematology centers offer access to novel agents including daratumumab, carfilzomib, and domestically-developed proteasome inhibitors at substantially lower costs. CAR-T cell therapy targeting BCMA is also available at select centers for relapsed/refractory disease.

流程Procedure steps

Step by step.

  1. 01

    Diagnosis & Risk Stratification

    Bone marrow biopsy, cytogenetics/FISH, serum free light chains, and imaging (PET-CT or whole-body MRI)

    Duration · 1-2 weeks
  2. 02

    Induction Chemotherapy

    4-6 cycles of VRd or similar triplet regimen to achieve deep response

    Duration · 4-6 months
  3. 03

    Autologous Stem Cell Transplant

    Stem cell collection, high-dose melphalan conditioning, and stem cell infusion

    Duration · 3-4 weeks
  4. 04

    Maintenance Therapy

    Lenalidomide maintenance until progression; high-risk patients may add proteasome inhibitor

    Duration · Ongoing 2+ years
Benefits
  • Access to novel agents and CAR-T at fraction of Western costs
  • Experienced transplant centers with high-volume programs
  • Domestically-produced targeted drugs improve affordability
  • Comprehensive supportive care including bone protection
Considerations
  • Transplant-related morbidity including infections
  • Treatment is not curative — relapse is expected
  • Peripheral neuropathy from proteasome inhibitors
  • Secondary malignancies with long-term lenalidomide use
下一步Next step

Ask the AI for hospitals that handle multiple myeloma treatment.

Ask AIRequest consultation

Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.